Literature DB >> 15378304

Neurorehabilitation in multiple sclerosis--what is the evidence-base?

Jürg Kesselring1.   

Abstract

Multiple sclerosis is associated with a variety of symptoms and functional deficits that result in a range of progressive impairments and handicap. The symptoms, which contribute to loss of independence and restrictions in the participation in social activities, are often responsible for a continuing decline in quality of life. The main objective of rehabilitation is, therefore, to ease the burden of symptoms by improving self-performance and independence. Compensation of functional deficits, adaptation and reconditioning, together with management of symptoms, impairment, emotional coping and self-estimation, are all important long-term objectives. Although rehabilitation has no direct influence on disease progression, recent studies indicate that this form of intervention improves personal activities and participation in social activities, thereby improving quality of life. The improvements often outlast the treatment period by several months. These findings suggest that quality of life is determined by disability and handicap more than by functional deficit and disease progression.

Entities:  

Mesh:

Year:  2004        PMID: 15378304     DOI: 10.1007/s00415-004-1405-0

Source DB:  PubMed          Journal:  J Neurol        ISSN: 0340-5354            Impact factor:   4.849


  27 in total

1.  Increased endothelin-1 plasma levels in patients with multiple sclerosis.

Authors:  T Haufschild; S G Shaw; J Kesselring; J Flammer
Journal:  J Neuroophthalmol       Date:  2001-03       Impact factor: 3.042

2.  Pathological laughing and crying in multiple sclerosis: a preliminary report suggesting a role for the prefrontal cortex.

Authors:  A Feinstein; P O'Connor; T Gray; K Feinstein
Journal:  Mult Scler       Date:  1999-04       Impact factor: 6.312

3.  Impact of neurorehabilitation on disability in patients with acutely and chronically disabling diseases of the nervous system measured by the Extended Barthel Index.

Authors:  M Jörger; S Beer; J Kesselring
Journal:  Neurorehabil Neural Repair       Date:  2001       Impact factor: 3.919

4.  Botulinum-A toxin for treating detrusor hyperreflexia in spinal cord injured patients: a new alternative to anticholinergic drugs? Preliminary results.

Authors:  B Schurch; M Stöhrer; G Kramer; D M Schmid; G Gaul; D Hauri
Journal:  J Urol       Date:  2000-09       Impact factor: 7.450

Review 5.  Methenamine hippurate for preventing urinary tract infections.

Authors:  B Lee; T Bhuta; J Craig; J Simpson
Journal:  Cochrane Database Syst Rev       Date:  2002

6.  The effects of anxiety on psychiatric morbidity in patients with multiple sclerosis.

Authors:  A Feinstein; P O'Connor; T Gray; K Feinstein
Journal:  Mult Scler       Date:  1999-10       Impact factor: 6.312

7.  Depression as a major symptom of multiple sclerosis.

Authors:  F A Whitlock; M M Siskind
Journal:  J Neurol Neurosurg Psychiatry       Date:  1980-10       Impact factor: 10.154

8.  Depression, cognitive impairment and social stress in multiple sclerosis.

Authors:  A C Gilchrist; F H Creed
Journal:  J Psychosom Res       Date:  1994-04       Impact factor: 3.006

9.  Inpatient rehabilitation in multiple sclerosis: do the benefits carry over into the community?

Authors:  J A Freeman; D W Langdon; J C Hobart; A J Thompson
Journal:  Neurology       Date:  1999-01-01       Impact factor: 9.910

10.  Published evidence favors the use of suprapubic catheters in pelvic colorectal surgery.

Authors:  Graham W Branagan; Brendan J Moran
Journal:  Dis Colon Rectum       Date:  2002-08       Impact factor: 4.585

View more
  2 in total

Review 1.  Life issues in multiple sclerosis.

Authors:  Rex D Simmons
Journal:  Nat Rev Neurol       Date:  2010-09-21       Impact factor: 42.937

Review 2.  Management of multiple sclerosis in adolescents - current treatment options and related adherence issues.

Authors:  Jean K Mah; Jennifer E Thannhauser
Journal:  Adolesc Health Med Ther       Date:  2010-06-17
  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.